Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009646 | 0.84 | PTGS2 (0.34) | PTGS2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4013337 | 0.84 | PTGS2 (0.30) | PTGS2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4010013 | 0.84 | PTGS2 (0.30) | PTGS2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4013460 | 0.84 | PTGS2 (0.34) | PTGS2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL4006455 | 0.83 | HTT (0.38) | PTGS2RORCKDM4EALDH1A1MAPT | |
| SCHEMBL4011512 | 0.82 | SLC22A12 (0.33) | — | |
| SCHEMBL4013447 | 0.76 | PTGS2 (0.33) | PTGS2RORC | |
| SCHEMBL4004291 | 0.75 | KDM4E (0.33) | RORCKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL695845 | 0.69 | L3MBTL1 (0.38) | PTGS2PTGER1KDM4EALDH1A1MAPT | |
| SCHEMBL4008319 | 0.65 | PTGS2 (0.32) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PTGS2 1766/4885TP53 234/4885PTGER1 2512/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PTGS2 1706/4885TP53 294/4885PTGER1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.